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Summary In this paper we analysed clinical, laboratory characteristics and outcome of patients
with haematological diseases who developed an Aspergillus niger infection, in a
multicentre study involving 14 Italian Haematological Divisions during a 10-year
period. The study recorded 194 consecutive microbiologically documented
aspergilloses, eight of which (4%) were due to A. niger, and were observed only in
five of the participating centres. The primary localization of infection was lung in seven
cases and paranasal sinus in one case. Seven patients died at the end of follow-up. The
death was mainly attributable to A. niger progression in six of them. Our study that
collected the largest number of cases of A. niger infection in haematological
malignancies confirms that this infrequent complication is characterized by a high
mortality rate.
Zusammenfassung In dieser Multizenterstudie von 14 italienischen Abteilungen fu¨r Ha¨matologie u¨ber
zehn Jahre hinweg wurden 194 dokumentierte Aspergillosen erfasst, von denen acht
(4%) durch Aspergillus niger bedingt waren; diese Fa¨lle traten nur in fu¨nf der beteiligten
Einrichtungen auf. Prima¨rlokalisation waren in sieben Fa¨llen die Lunge und in einem
die Nebenho¨hlen. Sieben Patienten verstarben am Ende der Beobachtungsperiode. Bei
sechs von diesen war u¨berwiegend die A. niger-Progression fu¨r den Tod verantwortlich.
Unsere Studie umfasst die gro¨ßte Zahl von A. niger-Infektionen bei ha¨matologischen
Grunderkrankungen und besta¨tigt, dass diese seltene Komplikation mit einer hohen
Mortalita¨t verknu¨pft ist.
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Schlu¨sselwo¨rter: Aspergillus niger, Aspergillose, Pneumonie, Lunge, Nasennebenho¨hle, Leuka¨mie.
Introduction
Invasive mould infections are a major cause of
morbidity and mortality in patients with haemato-
logical malignancies.1 The number of patients affec-
ted by malignancies who develop deep fungal
infections has dramatically increased during the
recent decades together with the use of more
aggressive chemotherapy regimes, which lead to a
longer duration of postchemotherapy neutropenia.2
This increase is probably due to multiple factors: host
defence impairments due to intensive cytotoxic chem-
otherapies, use of steroids or other immunosuppres-
sive agents (cyclosporin, azathioprin), increase of
environmental exposure, the use of parenteral nutri-
tion, the destruction of the mucous barriers due to
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chemotherapy or other invasive procedures, the use
of broad-spectrum antibiotics.3 The majority of inva-
sive mould infections occurs in patients with haem-
atological malignancy and particularly in acute
myeloid leukaemia patients.2
Among invasive fungal infection, Candida spp. have
been the most frequent cause in neutropenic patients,
but, while its incidence is substantially unchanged in
the years, an increase of invasive mould infections has
been observed in recent years due to an increase of
Aspergillus spp. infection.4 Among aspergillosis, Asper-
gillus niger represents a rare cause of infections in
patients with haematological diseases. In the immuno-
competent host this filamentous fungus constitutes the
most frequent aetiological agent isolated in cases of
otomycosis.5,6
In this retrospective analysis we reviewed the records
of eight patients affected by haematological malignan-
cies who developed an A. niger infection in order to
evaluate the underlying disorder, the clinical presenta-
tion of the disease and the factors that influenced the
outcome in these patients.
Patients and methods
Between January 1988 and December 1997, 194
microbiologically documented infections due to Asper-
gillus were observed in 14 Haematological Divisions
who participated in the study: 108 episodes were caused
by A. fumigatus (56%), 58 episodes by A. flavus (30%),
15 episodes by A. terreus (8%), four episodes by
A. versicolor (2%) and one episode by A. nidulans
(0.5%). An infection due to A. niger was documented
only in the remaining eight patients (4%).
The diagnosis of proven, probable or possible asper-
gillosis was made following the criteria of the EORTC/
MSG group.7
The charts of all patients with A. niger isolation were
examined and the following main parameters were
considered: demographic characteristics of patients,
type and stage of the malignancy, clinical symptoms
and signs of infection, radiological findings, site of
infection, laboratory findings (i.e. neutrophil count,
microbiological isolates, etc.), treatment administered,
outcome, autopsy findings.
Results
The characteristics of the eight patients with A. niger
infection are reported in Table 1.
They were seven males and one female with a
median age of 65 years (range 22–71). In six patients Ta
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the underlying haematological disease was represented
by acute leukaemia, myeloid in four patients and
lymphoid in the other two. The last two patients were
affected by lymphoma and aplastic anaemia, respect-
ively.
Seven patients underwent chemotherapy within
30 days before aspergillosis was diagnosed: five patients
received induction chemotherapy and two patients
salvage chemotherapy for haematological disease pro-
gression. Only the patient with aplastic anaemia did not
receive chemotherapy. This patient developed A. niger
pneumonia before the diagnosis of haematological
disease and the fungal complication represented the
first sign of his underlying condition. None of these
patients underwent bone marrow transplantation pro-
cedures. Three patients received steroids before A. niger
infection, with a methyl-prednisolone dosage of 60, 600
and 1600 mg respectively, for a median duration of
15 days (range 3–20). Seven patients were deeply
neutropenic (ANC <500 ll1), for a median of 14 days
(range 6–30). Six patients received oral antifungal
prophylaxis: in three cases with fluconazole, in two with
topic amphotericin B and in one case with topic
nystatin.
All signs and symptoms presented by patients are
reported in Table 1. All patients presented fever with a
median temperature of 38.5 C. In particular one
patient presented fever only, without other signs or
symptoms suggestive for fungal infection, and diagnosis
of aspergillosis was made at autopsy.
According to the EORTC/MSG criteria7 proven asper-
gillosis was diagnosed in four cases, probable in four
cases.
The primary site of infection was the lung in the
majority of cases, seven patients, while the last patient
had paranasal sinus infection with a concomitant
orbital involvement. Interestingly none of these eight
patients had an otomycosis.
Thorax X-ray exam was positive in four of the seven
patients with primary pulmonary aspergillosis. Thorax
CT-scan was performed only in those four patients with
positive thorax X-ray and it was suggestive for asper-
gillosis in all cases. In the other three patients with
negative thorax X-ray diagnosis was made only with
lung examination at autopsy.
In the patient with paranasal sinus infection, cranial
CT-scan showed a pattern compatible with aspergillosis.
Microbiological detection of A. niger was made from:
sputum in four patients, bronchoalveolar lavage fluid in
two patients, nasal plugging in one patient, and from
the culture of autoptic lung sample in one case.
Histopathological examination showing hyphae from
trans-bronchial biopsy specimen was performed in one
patient.
Autopsy was carried out in three patients only, and it
confirmed the diagnosis of aspergillosis in all cases.
Treatment and outcome of the eight patients with
A. niger infection are reported in Table 2.
Antifungal treatment was empirically administered in
seven of these patients after a median of 90 h of
unresponsive fever to broad-spectrum antibiotics (gen-
erally aminoglycoside plus cephalosporins and/or gly-
copeptide in those patients with central venous
catheter). One patient died of fungal infection progres-
sion on day 4 after onset of the symptoms without
receiving antifungal treatment. Deoxycholate ampho-
tericin B (AmB) was employed in six cases at a median
dose of 1 mg kg1 day1 (range 0.5–1.2). The total
median dose of AmB administered was 26.5 mg kg1
(range 10.7–40) for a median duration of 29 days
(range 11–54). One patient was treated with liposomal
AmB (l-AmB) for renal impairment (median daily dose
4 mg kg1).
Of the seven cases treated, two were responsive
with disappearance of fever and improvement of
clinical status, but one patient died after 55 days for
leukaemia progression. In the remaining five cases
aspergillosis progressed and patients died within
30 days from diagnosis. At 6 months from aspergil-
losis diagnosis only one patient was alive. Overall the
death was mainly attributable to A. niger in six cases
(75%).
Discussion
Despite the advances in antimicrobial therapy and
supportive care, invasive fungal infections (IFI) have
remained over the past decades a significant problem in
patients with haematological malignancies. IFI are
increasing in frequency in this population, and are also
occurring earlier during the course of chemotherapy.
Moreover, new fungi are increasingly recognized as
potentially lethal pathogens.8–15 Historically, Candida
spp. has represented the main cause of invasive fungal
infection. However, in recent years, autoptic studies
confirm that the incidence of invasive mould infections
is on the rise.4,16–18 Among the invasive mould
infections, aspergillosis is becoming the most relevant
cause of death in patients with haematological malig-
nancies, despite the availability of new antifungal
agents and new formulations of old agents.1,19–27
Of the more than 200 Aspergillus species known,
A. fumigatus and A. flavus are frequently noted to cause
infections in neutropenic patients. Conversely A. niger
Aspergillus niger infection in haematological malignancies
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is rarely demonstrated in immunocompromised
hosts.28,29
There are several reports on its detection in patients
suffering from otomycosis.5,6
Particularly A. niger is reported to be a frequent agent
of external otitis in categories of immunocompetent
subjects with mechanical removing devices or in sub-
jects working in gardens. Few case reports on the onset
of A. niger in haematological malignancies patients have
been published.28,29
In this study we identified among a large number of
haematological disease patients, eight cases of A. niger
infection and this observation allows some interesting
consideration.
In this subgroup of patients, pulmonary aspergillosis
is the most frequent complication and none of our
patients presented an otomycosis. These data suggest
that the behaviour of A. niger in immunocompromised
haematological patients appears to be similar than the
other more frequently observed Aspergillus species.30 We
confirm that patients with acute leukaemia, in partic-
ular myeloid subtypes, represent the highest risk
category.
Diagnostic procedures, both invasive and non-inva-
sive, are necessary to reduce the risk that the infection is
misdiagnosed or not identified. Frequently it is imposs-
ible to achieve a diagnosis with invasive procedures
because of the bad general clinical conditions of the
patient or because of thrombocytopenia. However,
radiological procedures alone give information that
does not always indicate whether an aspergillosis is
present or what the infectious organism is.
The outcome of this infection is heavily influenced
by the degree and duration of neutropenia. The
impairment of the immune response by underlying
haematological malignancies or immunosuppressive
therapy may play a role in the onset and diffusion of
aspergillosis, during the early phases of the treatment,
in colonized patients. In our small series, the majority of
patients developed A. niger complication during the first
induction treatment.
In the great majority of patients, amphotericin B was
the first line treatment. The treatment, most frequently
empirically started, was effective in 25% of patients,
while about 75% of patients died from fungal infection
within 30 days from diagnosis. The mortality rate is
higher than that observed in other larger series on cases
of invasive mould infections.30,31 Of course, the small
number of cases reported here does not allow any
statistical conclusion.
Although amphotericin B is the main antifungal
drug, other agents, i.e. itraconazole or voriconazole,
could be effective in the prevention and treatment of
invasive mould infections. Future studies should be
focused on preventive strategies aimed at reducing both
environmental and host risk factors.
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